Advertisement

Search Results

Advertisement



Your search for The matches 34612 pages

Showing 201 - 250


solid tumors
issues in oncology

The Real Cost Campaign May Have Prevented Thousands of Youths From Initiating E-Cigarette Use

The U.S. Food and Drug Administration’s (FDA) youth e-cigarette prevention campaign, known as The Real Cost, may have successfully reduced e-cigarette use among youth, according to a recent study published by MacMonegle et al in the American Journal of Preventive Medicine. Background The Real Cost...

breast cancer
issues in oncology

Receipt of Guideline-Concordant Care in Patients With Inflammatory Breast Cancer

Investigators may have uncovered the proportion of patients with inflammatory breast cancer who receive guideline-concordant care, according to a recent study published by Tadros et al in JAMA Network Open. Background Clinical practice guidelines currently recommend neoadjuvant systemic therapy...

sarcoma

High-Risk Rhabdomyosarcoma: Long-Term Outcomes With Maintenance Chemotherapy

As reported in the Journal of Clinical Oncology by Gianni Bisogno, MD, PhD, and colleagues, long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial showed significant survival advantages with the use of maintenance chemotherapy in pediatric patients with...

gynecologic cancers

Cervical Cancer Outcomes According to Urban vs Rural Residence

In a study reported as a research letter in JAMA Network Open, Amboree et al found that women with cervical cancer living in rural U.S. counties had poorer outcomes than those living in urban counties. Study Details The trial used data from the National Program of Cancer Registries and...

gynecologic cancers

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...

issues in oncology

Do Congenital Heart Defects Affect Cancer Risk in Newborns and Their Mothers?

Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality. Further, congenital heart defects in newborns may also signal an elevated cancer risk for their mothers. These findings were published recently by Huh...

lung cancer

MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC

The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...

gynecologic cancers
issues in oncology
immunotherapy

BVAC-C Plus Durvalumab May Show Potential in Patients With Recurrent Cervical Cancer

A novel treatment approach may improve outcomes in patients with recurrent or metastatic cervical cancer, according to new findings presented by Choi et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Recurrent cervical cancer remains a significant challenge,...

gynecologic cancers
issues in oncology
immunotherapy

Advances in Endometrial Cancer Detection, Treatment

Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.  Together, the two studies...

solid tumors

Atezolizumab Plus Carboplatin/Paclitaxel in Advanced Thymic Carcinoma

In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al found that atezolizumab plus carboplatin/paclitaxel showed promising results in patients with recurrent or metastatic thymic carcinoma. Study Details In the multicenter trial, 48 patients enrolled between June 2022 ...

skin cancer

Pembrolizumab and Bevacizumab in Untreated Melanoma Brain Metastases

In a phase II trial reported in Journal of Clinical Oncology, Weiss et al found that the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melanoma brain metastases. Study Details In the trial, 37 patients, enrolled at Yale Cancer Center and Moffitt...

lymphoma

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...

head and neck cancer
immunotherapy

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...

gynecologic cancers
genomics/genetics

Genomic Study Reveals Similarities, Differences in Ovarian Cancer Mutations Among Black, White Patients

Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....

bladder cancer

Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma

In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated...

gynecologic cancers

Cervical Precancer Incidence Decreases as HPV Vaccination Rates Rise

Recent findings from the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT), which were published by Gargano et al in the Morbidity and Mortality Weekly Report, revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women....

lung cancer
issues in oncology
genomics/genetics

Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC

Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...

solid tumors
issues in oncology
skin cancer

Study Finds No Clear Evidence That Red Wine Mitigates Cancer Risk

The consumption of alcohol has been associated with increased cancer risk, but red wine has been perceived by some as a healthier choice compared to white wine and other types of alcohol. Investigators evaluated whether the anticancer properties of red wine were greater in a recent study published...

breast cancer

Association of Pathogenic Variants With Cancer Mortality

In a study reported in the Journal of Clinical Oncology, Veenstra et al found that pathogenic variants (PVs) in ATM, CHEK2, or PALB2 were not associated with significant differences in mortality from breast, colorectal, or pancreatic cancer compared with the absence of such PVs. Study Details The...

Impact of Duration of Neoadjuvant Immunotherapy in MMRd Colorectal Cancer

In an analysis reported as a letter to the editor in The New England Journal of Medicine, Rousseau et al found a relationship between the duration of neoadjuvant immunotherapy and the likelihood of pathologic complete response in patients with localized mismatch repair–deficient (MMRd) colorectal...

kidney cancer

Nivolumab Plus Cabozantinib Continues to Show Superior Long-Term Outcomes in Advanced Renal Cell Carcinoma

The PD-1 inhibitor nivolumab plus the tyrosine kinase inhibitor cabozantinib continues to demonstrate a significant survival advantage over sunitinib alone in patients with previously untreated advanced renal cell carcinoma, according to data presented at the 2025 ASCO Genitourinary Cancers...

cns cancers
issues in oncology

Firefighters May Face Higher Risk of Gliomas Associated With Gene Mutations Caused by Haloalkanes

Among patients with gliomas, gene mutations related to exposure to certain chemical compounds may be more common in firefighters than in those with other occupations, according to a recent study published by Cannataro et al in Cancer. Background Certain chemical compounds have been known to cause...

supportive care
survivorship
cardio-oncology

Moderate-to-Vigorous Physical Activity May Lower Risk of Cardiovascular Disease–Related Mortality in Women With a Cancer History

Taking more daily steps and engaging in moderate-to-vigorous physical activity may both be associated with a reduced risk of cardiovascular disease–related mortality among postmenopausal women with a history of cancer, according to preliminary findings presented by Hyde et al at the American Heart...

lung cancer

Study Finds Wildfires Pose Health Threat for Patients Recovering From Lung Cancer Surgery

Studies have shown that not only does exposure to wildfire smoke, which contains fine particulate matter, increase the risk of developing lung cancer, it can also significantly reduce survival rates among patients recovering from lung cancer surgery. A large national study by researchers at the...

breast cancer

Genomic Differences and Treatment Inequities in Black and White Patients With Metastatic Breast Cancer

In a retrospective cohort study reported in JAMA Network Open, Podany et al identified differences in circulating tumor DNA (ctDNA) profiles, targeted therapy use, and survival outcomes in Black vs White patients with metastatic breast cancer. Study Details The U.S. multicenter study involved 1,327 ...

prostate cancer

Addition of Pembrolizumab to Chemotherapy for Previously Treated Metastatic Castration-Resistant Prostate Cancer

As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previously treated metastatic castration-resistant prostate cancer. Study Details In the global...

genomics/genetics
solid tumors
issues in oncology

Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings

Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...

colorectal cancer
issues in oncology

Liquid Biopsies Could Help Guide Colorectal Cancer Treatment

The use of a circulating tumor DNA (ctDNA) liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many patients to avoid chemotherapy, according to a recent study published by Tie et al in Nature Medicine. Background A liquid biopsy...

prostate cancer

Addition of ADT to SBRT in Hormone-Sensitive Oligorecurrent Prostate Cancer

In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that the addition of androgen-deprivation therapy (ADT) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate...

issues in oncology

Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...

global cancer care

Cancer Incidence and Mortality in Southeast Asia for 2022

In a study reported in The Lancet Oncology, Dee et al identified cancer incidence and mortality rates for 2022 in the countries of southeast Asia. Study Details The study involved data from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries...

cns cancers

Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma

The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...

head and neck cancer
issues in oncology
immunotherapy

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer

Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...

integrative oncology

Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment

Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...

cns cancers
genomics/genetics

Clonal and Subclonal Pathogenic Alterations at Diagnosis in High-Risk Neuroblastoma

In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...

ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor

In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...

breast cancer

Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate

In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...

issues in oncology
solid tumors

Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality

Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...

breast cancer
issues in oncology

Breast Cancer Mortality Rates May Have Stopped Declining

Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...

issues in oncology
global cancer care
health-care policy

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...

prostate cancer

Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer

A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...

solid tumors
breast cancer
issues in oncology
cardio-oncology
supportive care
symptom management

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer

A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...

prostate cancer
issues in oncology
genomics/genetics

Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone

Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...

hepatobiliary cancer
immunotherapy

Outcomes After Complete Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma

In a retrospective study reported in JAMA Network Open, Lim et al found that complete response to immunotherapy as first-line treatment of advanced hepatocellular carcinoma was associated with good outcomes. Study Details The study involved analysis of 228 patients who received atezolizumab and...

lung cancer

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...

solid tumors
immunotherapy

Combination of Immunotherapies for Advanced HPV-Associated Cancers

In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...

hepatobiliary cancer
issues in oncology

Novel Biomarkers May Improve Diagnosis of Gallbladder Cancer

Plasma proteins may be capable of distinguishing gallbladder cancer from cholecystitis, which could reduce unnecessary procedures and improve treatment options in patients with suspected gallbladder cancer, according to a recent study published by Nouairia et al in JHEP Reports. Gallbladder cancer...

gynecologic cancers
gastroesophageal cancer
head and neck cancer
skin cancer
issues in oncology

Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer

A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...

hematologic malignancies
multiple myeloma

MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma

In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...

lung cancer

Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC

In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...

Advertisement

Advertisement




Advertisement